JP7494115B2 - ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 - Google Patents

ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 Download PDF

Info

Publication number
JP7494115B2
JP7494115B2 JP2020532949A JP2020532949A JP7494115B2 JP 7494115 B2 JP7494115 B2 JP 7494115B2 JP 2020532949 A JP2020532949 A JP 2020532949A JP 2020532949 A JP2020532949 A JP 2020532949A JP 7494115 B2 JP7494115 B2 JP 7494115B2
Authority
JP
Japan
Prior art keywords
bont
toxin
modified
seq
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020532949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506824A5 (https=
JP2021506824A (ja
Inventor
ジョセフ ティー バルビエリ
エリック エイ ジョンソン
サビーヌ ペレット
ウィリアム エイチ テップ
アマンダ プルゼドペルスキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of JP2021506824A publication Critical patent/JP2021506824A/ja
Publication of JP2021506824A5 publication Critical patent/JP2021506824A5/ja
Priority to JP2023087721A priority Critical patent/JP7797441B2/ja
Application granted granted Critical
Publication of JP7494115B2 publication Critical patent/JP7494115B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020532949A 2017-12-15 2018-12-17 ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒 Active JP7494115B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023087721A JP7797441B2 (ja) 2017-12-15 2023-05-29 ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599444P 2017-12-15 2017-12-15
US62/599,444 2017-12-15
PCT/US2018/066033 WO2019118974A2 (en) 2017-12-15 2018-12-17 Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023087721A Division JP7797441B2 (ja) 2017-12-15 2023-05-29 ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒

Publications (3)

Publication Number Publication Date
JP2021506824A JP2021506824A (ja) 2021-02-22
JP2021506824A5 JP2021506824A5 (https=) 2022-02-07
JP7494115B2 true JP7494115B2 (ja) 2024-06-03

Family

ID=66819031

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020532949A Active JP7494115B2 (ja) 2017-12-15 2018-12-17 ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒
JP2023087721A Active JP7797441B2 (ja) 2017-12-15 2023-05-29 ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023087721A Active JP7797441B2 (ja) 2017-12-15 2023-05-29 ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒

Country Status (5)

Country Link
US (2) US11491239B2 (https=)
EP (1) EP3723784A4 (https=)
JP (2) JP7494115B2 (https=)
CN (2) CN119954917A (https=)
WO (1) WO2019118974A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
WO2020024002A1 (en) * 2018-07-31 2020-02-06 Snoretox Pty Ltd Pegylated tetanus neurotoxins and treatment of hypotonia
US12344635B2 (en) 2020-03-24 2025-07-01 The Medical College Of Wisconsin, Inc. COVID-19 vaccine
BR112022024303A2 (pt) 2020-05-30 2023-01-31 Prime Bio Inc Composição de vacina recombinante oral/sublingual/nasal, candidatos a vacina recombinante, e método de imunização contra a covid-19
WO2022083585A1 (zh) * 2020-10-20 2022-04-28 上海瑞宙生物科技有限公司 一种蛋白多糖结合物及其应用
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
CN115192702B (zh) * 2022-06-22 2025-07-15 上海赛伦生物技术股份有限公司 一种破伤风修饰性mRNA疫苗及其制备方法
CN115304673B (zh) * 2022-06-24 2024-10-01 上海赛伦生物技术股份有限公司 一种马抗破伤风特异性免疫球蛋白F(ab’)2的纯化方法及其应用
WO2026015556A1 (en) * 2024-07-08 2026-01-15 The Medical College Of Wisconsin, Inc. BoNT AND TeNT POLYPEPTIDE FRAGMENTS AND/OR VARIANTS, COMPOSITIONS, POLYNUCLEOTIDES, VACCINES, AND CONJUGATE VACCINE PLATFORMS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503059A (ja) 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス， テクノロジー アンド メディシン 破傷風毒素ポリペプチド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1232304C (zh) * 1996-03-23 2005-12-21 财团法人阪大微生物病研究会 破伤风毒素功能性片段抗原和破伤风疫苗
ATE348178T1 (de) * 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8853360B2 (en) * 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
US12344635B2 (en) 2020-03-24 2025-07-01 The Medical College Of Wisconsin, Inc. COVID-19 vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503059A (ja) 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス， テクノロジー アンド メディシン 破傷風毒素ポリペプチド

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Biochemistry，1994年，Vol. 33，pp.7014-7020
Biochemistry，2012年，Vol. 51，pp.3941-3947
Infect. Immun.，2014年，Vol. 82, No. 2，pp.873-881

Also Published As

Publication number Publication date
US20200384120A1 (en) 2020-12-10
CN119954917A (zh) 2025-05-09
CN111479821A (zh) 2020-07-31
US11491239B2 (en) 2022-11-08
JP2023123432A (ja) 2023-09-05
WO2019118974A4 (en) 2019-10-31
CN111479821B (zh) 2024-12-31
US20240139332A1 (en) 2024-05-02
JP7797441B2 (ja) 2026-01-13
WO2019118974A2 (en) 2019-06-20
JP2021506824A (ja) 2021-02-22
US12611464B2 (en) 2026-04-28
EP3723784A2 (en) 2020-10-21
WO2019118974A3 (en) 2019-08-15
EP3723784A4 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
JP7797441B2 (ja) ワクチン及びコンジュゲートワクチンプラットフォームとしての改変されたクロストリジウム神経毒
JP6656171B2 (ja) 組換えボツリヌス菌神経毒の生産
US8883172B2 (en) Chemically modified peptides with improved immunogenicity
Webb et al. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3
EP2844283B1 (en) Clostridium difficile antigens
US8372405B2 (en) Proteins with improved solubility and methods for producing and using same
CN110913883A (zh) 包含金黄色葡萄球菌杀白细胞素luka和lukb来源的多肽的免疫原性组合物
Li et al. Mutagenesis and immunological evaluation of group A streptococcal C5a peptidase as an antigen for vaccine development and as a carrier protein for glycoconjugate vaccine design
US7820411B2 (en) Escherichia coli-derived vaccine and therapy against botulism
WO2009113664A1 (ja) 組換え皮膚壊死トキソイドを含有する豚萎縮性鼻炎用薬剤
Du et al. Clostridium perfringens epsilon prototoxin mutant rpETXY30A/Y71A/H106P/Y196A as a vaccine candidate against enterotoxemia
CN116438193A (zh) OmpA突变增强百日咳博德特氏菌中OMV产生
JP7303791B2 (ja) スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
CN105705514A (zh) 用于治疗艰难梭状芽孢杆菌相关疾病的组成物及方法
WO2026015556A1 (en) BoNT AND TeNT POLYPEPTIDE FRAGMENTS AND/OR VARIANTS, COMPOSITIONS, POLYNUCLEOTIDES, VACCINES, AND CONJUGATE VACCINE PLATFORMS
Kumar Singh et al. Characterization of LC-HCC fusion protein of botulinum neurotoxin type A
CN101445789B (zh) 显性抑制突变体f427n作为炭疽毒素抑制剂及疫苗的应用
CN101392232B (zh) 显性抑制突变体f427d作为炭疽芽孢杆菌毒素抑制剂及疫苗的应用
WO2012054879A1 (en) Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240422

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240522

R150 Certificate of patent or registration of utility model

Ref document number: 7494115

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150